New Feature: See every earnings report in one clear view

Heron Therapeutics, Inc.

Contributing Author

Recent Articles by Heron Therapeutics, Inc.

Aug-10	Heron Therapeutics Announces Second Quarter 2026 Financial Results HRTX -31.74% GlobeNewswire
Jul-27	Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026 HRTX GlobeNewswire
Jun-02	U.S. District Court Issues Decision Regarding CINVANTI Patents HRTX -45.60% GlobeNewswire
May-11	Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance HRTX -21.05% GlobeNewswire
Apr-27	Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026 HRTX GlobeNewswire
Feb-26	Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results HRTX +11.11% GlobeNewswire
Feb-17	Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 HRTX GlobeNewswire
Jan-09	Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF Largest Contributor to Q4 Growth HRTX +9.45% GlobeNewswire
Dec-04	Heron Therapeutics Announces Inclusion of APONVIE (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) HRTX GlobeNewswire
Nov-04	Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress HRTX GlobeNewswire
Oct-29	Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors HRTX GlobeNewswire
Oct-21	Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 HRTX HRTX -8.46% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)